GATE-101 / Gate Neurosciences - LARVOL DELTA

Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers (clinicaltrials.gov) - P1 | N=18 | Terminated | Sponsor: Gate Neurosciences, Inc | N=40 ➔ 18 | Trial completion date: Dec 2021 ➔ Aug 2021 | Recruiting ➔ Terminated; Reached biomarker endpoint

Enrollment change • Trial completion date • Trial termination • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: Gate Neurosciences, Inc; Trial completion date: Jun 2021 ➔ Dec 2021; Trial primary completion date: Apr 2021 ➔ Oct 2021

Clinical • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry